

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3247526

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	GILEAD PALO ALTO, INC.	05/11/2011
RECEIVING PARTY DATA		
Name:	Gilead Sciences, Inc.	
Street Address:	333 Lakeside Dr.	
City:	Foster City	
State/Country:	CALIFORNIA	
Postal Code:	94404	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14533025
CORRESPONDENCE DATA		
Fax Number:	(650)522-5575	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	650-574-3000	
Email:	susan.ahearn@gilead.com	
Correspondent Name:	GILEAD SCIENCES, INC.	
Address Line 1:	333 LAKESIDE DR.	
Address Line 4:	FOSTER CITY, CALIFORNIA 94404	
ATTORNEY DOCKET NUMBER:	02-0479-US-CON5	
NAME OF SUBMITTER:	BRIAN LEWIS	
SIGNATURE:	/Brian Lewis, Reg. No. 32,502/	
DATE SIGNED:	03/02/2015	
Total Attachments: 5		
source=02-0479-CON3_Assignment_GPA_to_GSI#page1.tif		
source=02-0479-CON3_Assignment_GPA_to_GSI#page2.tif		
source=02-0479-CON3_Assignment_GPA_to_GSI#page3.tif		
source=02-0479-CON3_Assignment_GPA_to_GSI#page4.tif		
source=02-0479-CON3_Assignment_GPA_to_GSI#page5.tif		


ASSIGNMENT - WORLDWIDE

WHEREAS Gilead Palo Alto, Inc., of 333 Lakeside Drive, Foster City, California 94404, (hereinafter "Assignor") is the owner of the Patents or Patent Applications, both U.S. and all foreign countries, listed in Exhibit A, as well as the inventions set forth therein, by virtue of a merger of Apex Merger Sub, Inc. with and into CV Therapeutics, Inc., under the name Gilead Palo Alto, Inc.;

WHEREAS Gilead Sciences, Inc., of 333 Lakeside Drive, Foster City, California 94404, (hereinafter referred to singly and collectively as "Assignee") is desirous of acquiring the full right, title and interest in and to said inventions and in and to said Patents or Patent Applications for U.S. and all foreign countries and especially the countries listed in Exhibit A;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by Assignor, Assignor has sold, assigned, transferred and set over, and by these presents hereby sells, assigns, transfers and sets over to Assignee the entire right, title and interest in and to said Inventions for U.S. and all foreign countries, and in and to said Patents and Patent Applications listed in Exhibit A, including any and all priority applications, divisional, continuation, continuation-in-part, reissues or extensions thereof, to be held and enjoyed by Assignee for its own use as fully and entirely as the same would have been held and enjoyed by Assignor had this assignment not been made; the Commissioner or Director of U.S. and each foreign Patent Office is hereby authorized to transfer Assignee's interest to said Patents or Patent Applications to said Assignee in accordance herewith; this assignment being under covenant, not only that full power to make the same is had by the Assignor, Assignor hereby undertakes to execute and deliver to Assignee upon request all lawful documents which may be requested by Assignee, and to furnish Assignee with all facts relating to said invention as may be requested.

Executed this 11th day of May, 2011.


Signature

Daniel W. Collins

Name

Sr. Director, Intellectual Property

Title

for

GILEAD PALO ALTO, INC.

333 Lakeside Drive

Foster City, California 94404

(ASSIGNOR)

State of California

County of San Mateo

On May 11, 2011 before me, Susan Ahearn
(date) (insert name and title of the officer)


personally appeared Daniel W. Collins
(name(s) of signer(s))

who proved to me on the basis of satisfactory evidence to be the person~~(s)~~ whose name~~(s)~~
is/~~are~~ subscribed to the within instrument and acknowledged to me that he/~~she/they~~ executed
the same in his/~~her/their~~ authorized capacity~~(ies)~~, and that by his/~~her/their~~ signature~~(s)~~ on the
instrument the person~~(s)~~, or the entity upon behalf of which the person~~(s)~~ acted, executed the
instrument.


I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing
paragraph is true and correct.

WITNESS my hand and official seal.

Signature Susan Ahearn (Seal)



Executed this 11th day of May, 2011


Signature

Daniel W. Collins

Name

Sr. Director, Intellectual Property

Title

for

GILEAD SCIENCES, INC.

333 Lakeside Drive

Foster City, California 94404

(ASSIGNEE)

State of California

County of San Mateo

On May 11, 2011 before me, Susan Ahearn
(date) (insert name and title of the officer)

personally appeared Daniel W. Collins
(name(s) of signer(s))

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/~~are~~ subscribed to the within instrument and acknowledged to me that he/~~she/they~~ executed the same in his/~~her/their~~ authorized capacity(ies), and that by his/~~her/their~~ signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Susan Ahearn (Seal)




EXHIBIT A

Atty. Dkt. No.	Gilead Ref. No.	Appl. No.	Patent No.	Title	Country
045710-1800	08-0265-PRO	61/101043		METHOD OF MULTIDETECTOR COMPUTED TOMOGRAPHY	United States of America
045710-1801	08-0265	12/569643		METHOD OF MULTIDETECTOR COMPUTED TOMOGRAPHY	United States of America
045710-1903	05-0220-PRO	60/765114		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
045710-1905	05-0220 P 2	60/801857		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
045710-1900	05-220	11/701699	7732595	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
045710-1901	05-0220-CIP	11/750295	7671192	PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
045710-1902	05-0220-CON	12/687077		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
045710-1904	05-0220-CON	12/765623		PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS	United States of America
045710-1950	02-0479-PRO	60/399176		MYOCARDIAL PERFUSION IMAGING USING A2A RECEPTOR AGONISTS	United States of America
045710-1954	02-0479-PRO-2	60/399177		LOW DOSAGE MYOCARDIAL PERFUSION IMAGING AGENT	United States of America
045710-1955	02-479 Provisional A	60/426902		LOW DOSAGE MYOCARDIAL PERFUSION IMAGING AGENT	United States of America
045710-1956	02-0479 Provisional B	60/459803		MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
045710-1951	02-0479-C	10/629368	7683037	MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
045710-1952	02-0479-E	10/766403		MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	United States of America
045710-1953	02-0479-CON	12/695096		MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
045710-1957	02-479-E-CON	12/749328		MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS	United States of America
045710-2000	99-423 S3	11/588834	7655637	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2001	99-423-S4	12/637311		N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2002	99-423	09/338185	6403567	N-PYRAZOLE A2A ADENOSINE RECEPTOR AGONISTS	United States of America
045710-2003	99-423-S	10/018446	6642210	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2004	99-423 S1	10/652378	7183264	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2005	99-423-S-2	11/252760	7144872	N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2006	99-423-S4	12/968110		N-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America

045710-2050	99-424-T3	12/491791		C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2051	99-0424	09/338327	6214807	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2052	99-424-E	09/812176	6855818	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2053	99-424-T	10/018758	6770634	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2054	99-424-T1	10/813535	7109180	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2055	99-424-T-2	11/522120	7553823	C-PYRAZOLE A2A RECEPTOR AGONISTS	United States of America
045710-2100	00-0078	60/184296		PARTIAL A2A ADENOSINE RECEPTOR (ADOR) AGONIST	United States of America
045710-2101	00-0078-A	60/219876		LOW AFFINITY A2A RECEPTOR AGONISTS	United States of America
045710-2102	00-0078-B	09/792617		PARTIAL A2A ADENOSINE RECEPTOR (ADOR) AGONIST	United States of America
045710-2103	00-0078-D1	11/070768	7582617	MYOCARDIAL PERFUSION IMAGING METHOD	United States of America
045710-2104	00-0078-D-CON	12/435176		METHOD OF IDENTIFYING PATRIAL AGONISTS OF THE A2A RECEPTOR	United States of America
045710-2105	00-0078-D	10/614702		METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2A RECEPTOR	United States of America
045710-2250	04-0869	60/620577		USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
045710-2251	04-869-A	11/253322	7655636	USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
045710-2252	04-0869-CON	12/637583		USE OF A2A ADENOSINE RECEPTOR AGONISTS	United States of America
045710-2351	06-0454-A	11/766964		USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA	United States of America
045710-2400/X	06-0222	60/841842		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	United States of America
045710-2401	06-0222	11/848743		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	United States of America
045710-2402	06-0230	11/864437		METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE	United States of America
045710-2403	06-0222-US-CIP	12/163099		METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS	United States of America
045710-2500/X		60/878529		MYOCARDIAL PERFUSION IMAGING	United States of America
045710-2501	07-0237	11/969047		MYOCARDIAL PERFUSION IMAGING	United States of America